No Carolina / NY / Florida
Ph: 561.316.3330

Akadeum Life Sciences Release their Revolutionary Human T cell Activation and Expansion Kit

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • Activation and expansion take place at the top surface of the vessel, as T cells expand, they gently fall to the bottom preventing overstimulation and producing a higher cell yield of healthier cells.
  • This kit is compatible with a wide variety of cell culture systems, including standard well plates, specialty plates (such as Wilson Wolf G-Rex®), or gas-permeable bags, making it easily adaptable to a variety of workflows.
  • Due to the natural buoyancy of the microbubbles, the positively selected T cells then gently float to the top of the suspension.

Akadeum Life Sciences, the global leaders in buoyancy-based cell separation technology, have today announced the release of their ‘Human T Cell Activation & Expansion Kit’ with Buoyancy Activated Cell Sorting (BACS) microbubbles. The first-of-its-kind kit is designed to isolate, activate, and expand T cells from a sample in one simple workflow.

In 2023, CAR T cell therapy can cost between $500,000 and $1,000,000. Being one of the most expensive Medicare diagnosis-related drugs, the collection and manufacturing of T cells plays a large role in this excessive cost. Akadeum Life Sciences microbubble technology provides a more economical, cost-effective solution that is faster, and more adept at maintaining cell physiology. This powerful kit uses BACS microbubble technology to isolate highly pure populations of T cells, activate, and expand them for use in cell therapy.

Current cell isolation methods include magnetic activated cell separation (MACS®) and fluorescence-activated cell sorting (FACS). These techniques are well established yet have limitations, time-consuming workflows, are expensive, and can provide unhealthy cells which can hinder scientific developments. By sidestepping the negative effects of legacy methods, Akadeum’s activation and expansion microbubbles provide scientists and researchers with a quick, more efficacious, and cost-effective solution, ultimately allowing them to provide better treatments for patients.

T cells are labelled with an antibody cocktail targeting CD3 and CD28 co-stimulation to which the activation and expansion microbubbles bind. Due to the natural buoyancy of the microbubbles, the positively selected T cells then gently float to the top of the suspension. Activation and expansion take place at the top surface of the vessel, as T cells expand, they gently fall to the bottom preventing overstimulation and producing a higher cell yield of healthier cells.

This kit is compatible with a wide variety of cell culture systems, including standard well plates, specialty plates (such as Wilson Wolf G-Rex®), or gas-permeable bags, making it easily adaptable to a variety of workflows.

Brandon McNaughton, PhD., Chief Executive Officer and Co-Founder of Akadeum, comments: “Manufacturing and workflow practices need to catch up with the pioneering scientific advancements taking place in the oncology field. This gentle and ecofriendly process has the potential to save cell and gene therapy company’s valuable effort and time, transforming current solutions into more effective and economical treatments. Akadeum’s ‘Human T Cell Activation & Expansion Kit’ is an addition to our expanding portfolio of products. This launch also reinforces Akadeum’s goal of revolutionizing the cell separation industry, propelling us one step closer to getting our product to clinical trials.”

Casey Wegner, Vice President of R&D at Akadeum, added: “The isolation, activation, and expansion of highly purified cells has become a necessity for CAR T cell therapy. The gentle microbubble floatation process not only produces healthier cells, but is also a quicker, more efficient, and cost effective solution compared to outdated legacy methods. Our kit rapidly simplifies, optimizes, and streamlines the cell therapy workflow for professionals, ultimately making cell and gene therapy available for all of those in need.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Abu Dhabi Issues First BioTech Inventor-Class Golden Visa to Catalyze “Made-In-Abu-Dhabi IP” to Rockefeller University Inventor Dr Kambiz Shekdar, PhD

Dr Kambiz Shekdar said: "I gratefully take this opportunity as my solemn commitment to help build up the BioTech sector in Abu Dhabi with the same home-grown can-do-and-have-done record of accomplishment demonstrated by Emirati leadership, its people, and nation, and to do so collegially with the best of the best of the world's human capital across frontier technologies who, like myself, are drawn to the UAE with the thirst to pioneer and build better like only possible in the red-hot entrepreneurial climate of the UAE."

Activation Capital Introduces ‘Frontier BioHealth’ to Catalyze Life Science Startups

"We celebrate the growing base of research and technological advances within the region's health and life sciences sector," said Chandra Briggman, President and CEO of Activation Capital.

Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)

Investigator-Initiated Phase 2 study is being conducted at Northwestern University in cooperation with Moleculin. Trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune "memory" in glioblastoma animal models

By using this website you agree to accept Medical Device News Magazine Privacy Policy